COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Identifieur interne : 000B03 ( an2020/Analysis ); précédent : 000B02; suivant : 000B04COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
Auteurs : Dan Zhou [République populaire de Chine] ; Sheng-Ming Dai [République populaire de Chine] ; Qiang Tong [République populaire de Chine]Source :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2020.
Abstract
A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.
DOI: 10.1093/jac/dkaa114
PubMed: 32196083
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000235
- to stream PubMed, to step Curation: 000235
- to stream PubMed, to step Checkpoint: 000A38
- to stream Ncbi, to step Merge: 001369
- to stream Ncbi, to step Curation: 001369
- to stream Ncbi, to step Checkpoint: 001369
- to stream Main, to step Merge: 000B05
- to stream Main, to step Curation: 000B03
- to stream Main, to step Exploration: 000B03
- to stream an2020, to step Extraction: 000B03
Links to Exploration step
pubmed:32196083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.</title><author><name sortKey="Zhou, Dan" sort="Zhou, Dan" uniqKey="Zhou D" first="Dan" last="Zhou">Dan Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Dai, Sheng Ming" sort="Dai, Sheng Ming" uniqKey="Dai S" first="Sheng-Ming" last="Dai">Sheng-Ming Dai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Tong, Qiang" sort="Tong, Qiang" uniqKey="Tong Q" first="Qiang" last="Tong">Qiang Tong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32196083</idno><idno type="pmid">32196083</idno><idno type="doi">10.1093/jac/dkaa114</idno><idno type="wicri:Area/PubMed/Corpus">000235</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000235</idno><idno type="wicri:Area/PubMed/Curation">000235</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000235</idno><idno type="wicri:Area/PubMed/Checkpoint">000A38</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A38</idno><idno type="wicri:Area/Ncbi/Merge">001369</idno><idno type="wicri:Area/Ncbi/Curation">001369</idno><idno type="wicri:Area/Ncbi/Checkpoint">001369</idno><idno type="wicri:Area/Main/Merge">000B05</idno><idno type="wicri:Area/Main/Curation">000B03</idno><idno type="wicri:Area/Main/Exploration">000B03</idno><idno type="wicri:Area/an2020/Extraction">000B03</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.</title><author><name sortKey="Zhou, Dan" sort="Zhou, Dan" uniqKey="Zhou D" first="Dan" last="Zhou">Dan Zhou</name><affiliation wicri:level="1"><nlm:affiliation>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Dai, Sheng Ming" sort="Dai, Sheng Ming" uniqKey="Dai S" first="Sheng-Ming" last="Dai">Sheng-Ming Dai</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Tong, Qiang" sort="Tong, Qiang" uniqKey="Tong Q" first="Qiang" last="Tong">Qiang Tong</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology & Immunology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release. There is an urgent need to identify safe and effective drugs for treatment. Chloroquine (CQ) exhibits a promising inhibitory effect. However, the clinical use of CQ can cause severe side effects. We propose that hydroxychloroquine (HCQ), which exhibits an antiviral effect highly similar to that of CQ, could serve as a better therapeutic approach. HCQ is likely to attenuate the severe progression of COVID-19, inhibiting the cytokine storm by suppressing T cell activation. It has a safer clinical profile and is suitable for those who are pregnant. It is cheaper and more readily available in China. We herein strongly urge that clinical trials are performed to assess the preventive effects of HCQ in both disease infection and progression.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhou, Dan" sort="Zhou, Dan" uniqKey="Zhou D" first="Dan" last="Zhou">Dan Zhou</name></noRegion><name sortKey="Dai, Sheng Ming" sort="Dai, Sheng Ming" uniqKey="Dai S" first="Sheng-Ming" last="Dai">Sheng-Ming Dai</name><name sortKey="Tong, Qiang" sort="Tong, Qiang" uniqKey="Tong Q" first="Qiang" last="Tong">Qiang Tong</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/an2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd -nk 000B03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= an2020
|étape= Analysis
|type= RBID
|clé= pubmed:32196083
|texte= COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/an2020/Analysis/RBID.i -Sk "pubmed:32196083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/an2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |